Celldex Therapeutics Stock
Celldex Therapeutics Stock
Celldex Therapeutics gained 1.610% today.
Our community is currently high on Celldex Therapeutics with 8 Buy predictions and 3 Sell predictions.
With a target price of 38 € there is a hugely positive potential of 50.79% for Celldex Therapeutics compared to the current price of 25.2 €.
So far the community has only identified positive things for Celldex Therapeutics stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Celldex Therapeutics in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Celldex Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Celldex Therapeutics | 1.610% | 14.815% | 16.981% | 34.783% | 12.727% | -42.352% | 13.866% |
| Larimar Therapeutics Inc. | -1.720% | 20.526% | 65.942% | 77.519% | 37.952% | -21.034% | -67.050% |
| Vaxart Inc. | 0.000% | 5.660% | 33.333% | 25.786% | 100.000% | -31.524% | -88.186% |
| Achieve Life Sciences Inc. | 6.280% | 0.412% | 5.324% | 37.336% | -1.081% | -16.856% | -61.064% |
Comments
Celldex Therapeutics (CLDX) had its "buy" rating reaffirmed by Stifel Nicolaus. They now have a $68.00 price target on the stock, up from $58.00.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) had its price target raised by analysts at Barclays PLC from $21.00 to $24.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) had its price target lowered by analysts at Barclays PLC from $25.00 to $21.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
News
Celldex Therapeutics SVPs Engage In Heavy Transactions
On Dec. 4, 2025, Freddy A. Jimenez, Senior Vice President & General Counsel of Celldex Therapeutics (NASDAQ:CLDX), executed an open-market sale of 4,166 insider shares. See SEC Form 4 filing.
